Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Clarity Pharmaceuticals Ltd. (AU:CU6)
ASX:CU6
RESEARCH TOOLSreports
Clarity Pharmaceuticals Ltd. (CU6) Share Price & Analysis
30 Followers
CU6 Stock Chart & Stats
Day’s RangeAU$0 - AU$0
52-Week RangeAU$0.67 - AU$3.05
Previous CloseAU$2.52
Volume84.25K
Average Volume (3M)550.06K
Market Cap
AU$683.17M
Enterprise ValueAU$590.83M
Total Cash (Recent Filing)AU$92.34M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)-21.6
Beta1.27
Next Earnings
Aug 21, 2024EPS Estimate
-AU$0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. Volume550,057
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$3.11Price Target Upside20.08% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Clarity Pharmaceuticals Ltd. News
PremiumCompany Announcements
Clarity Pharmaceuticals Secures $121 Million Funding
PremiumCompany Announcements
Clarity Pharmaceuticals Announces Key Shareholder UpdatePremiumCompany Announcements
Clarity Pharmaceuticals Seeks New Securities Quotation
PremiumCompany Announcements
Clarity Pharmaceuticals Announces Ownership Shift
PremiumCompany Announcements
Clarity Pharmaceuticals Seeks New ASX QuotationPremiumCompany Announcements
Clarity Pharmaceuticals Advances Cancer Trials with New Supply DealOptions Prices
Currently, No data available
---
Ownership Overview
1.32% Insiders
0.00% Mutual Funds
0.00% Other Institutional Investors
98.68% Public Companies and
Individual Investors
CU6 FAQ
What was Clarity Pharmaceuticals Ltd.’s price range in the past 12 months?
Clarity Pharmaceuticals Ltd. lowest share price was AU$0.67 and its highest was AU$3.05 in the past 12 months.
What is Clarity Pharmaceuticals Ltd.’s market cap?
Currently, no data Available
When is Clarity Pharmaceuticals Ltd.’s upcoming earnings report date?
Clarity Pharmaceuticals Ltd.’s upcoming earnings report date is Aug 21, 2024 which is in 115 days.
How were Clarity Pharmaceuticals Ltd.’s earnings last quarter?
Clarity Pharmaceuticals Ltd. released its earnings results on Feb 29, 2024. The company reported -AU$0.066 earnings per share for the quarter, missing the consensus estimate of -AU$0.057 by -AU$0.009.
Is Clarity Pharmaceuticals Ltd. overvalued?
According to Wall Street analysts Clarity Pharmaceuticals Ltd.’s price is currently Undervalued.
Does Clarity Pharmaceuticals Ltd. pay dividends?
Clarity Pharmaceuticals Ltd. does not currently pay dividends.
What is Clarity Pharmaceuticals Ltd.’s EPS estimate?
Clarity Pharmaceuticals Ltd.’s EPS estimate is -AU$0.05.
How many shares outstanding does Clarity Pharmaceuticals Ltd. have?
Clarity Pharmaceuticals Ltd. has 271,098,480 shares outstanding.
What happened to Clarity Pharmaceuticals Ltd.’s price movement after its last earnings report?
Clarity Pharmaceuticals Ltd. reported an EPS of -AU$0.066 in its last earnings report, missing expectations of -AU$0.057. Following the earnings report the stock price went down -1.027%.
Which hedge fund is a major shareholder of Clarity Pharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in AU:CU6
---
Clarity Pharmaceuticals Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$3.11 (20.08% Upside)
AU$3.11 (20.08% Upside)
Blogger Sentiment
Bullish
AU:CU6 Sentiment 97%
Sector Average 70%
Sector Average 70%
Technicals
SMA
Positive
20 days / 200 days
Momentum
222.18%
12-Months-Change
Fundamentals
Return on Equity
-45.33%
Trailing 12-Months
Asset Growth
-35.15%
Trailing 12-Months
Company Description
Clarity Pharmaceuticals Ltd.
Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, based on its platform SAR Technology. The SAR technology is ideally suited for use with copper isotopes, enabling superior imaging and therapeutic characteristics of radiopharmaceutical products and addressing the current manufacturing and logistical limitations in the growth of the radiopharmaceutical sector in oncology.
---
CU6 Stock 12 Months Forecast
Average Price Target
AU$3.11
▲(20.08% Upside)
Technical Analysis
LBT Innovations Limited
―
Althea Group Holdings Ltd.
―
Micro-X Ltd.
―
Alcidion Group Limited
―
Best Analysts Covering CU6
1 Year
1 Year Success Rate
9/11 ratings generated profit
1 Year Average Return
+111.95%
reiterated a buy rating 20 days ago
Copying Melissa Benson's trades and holding each position for 1 Year would result in 81.82% of your transactions generating a profit, with an average return of +111.95% per trade.
---